Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Riccardo Bomben; Francesca Maria Rossi; Filippo Vit; Tamara Bittolo; Antonella Zucchetto; Robel Papotti; Erika Tissino; Federico Pozzo; Massimo Degan; Jerry Polesel; Pietro Bulian; Roberto Marasca; Gianluigi Reda; Luca Laurenti; Jacopo Olivieri; Annalisa Chiarenza; Roberta Laureana; Massimiliano Postorino; Maria Ilaria Del Principe; Antonio Cuneo; Massimo Gentile; Fortunato Morabito; Gilberto Fronza; Agostino Tafuri; Francesco Zaja; Robin Foà; Francesco Di Raimondo; Giovanni Del Poeta; Valter Gattei

doi:10.1038/s41375-023-01845-9

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18.

Authors

Riccardo Bomben¹, Francesca Maria Rossi², Filippo Vit², Tamara Bittolo², Antonella Zucchetto², Robel Papotti^{3

2}, Erika Tissino², Federico Pozzo², Massimo Degan², Jerry Polesel⁴, Pietro Bulian², Roberto Marasca^{5

6}, Gianluigi Reda⁷, Luca Laurenti⁸, Jacopo Olivieri⁹, Annalisa Chiarenza¹⁰, Roberta Laureana¹¹, Massimiliano Postorino¹¹, Maria Ilaria Del Principe¹¹, Antonio Cuneo¹², Massimo Gentile^{13

14}, Fortunato Morabito^{13

15}, Gilberto Fronza¹⁶, Agostino Tafuri¹⁷, Francesco Zaja¹⁸, Robin Foà¹⁹, Francesco Di Raimondo¹⁰, Giovanni Del Poeta¹¹, Valter Gattei²⁰

Affiliations

¹ Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy. rbomben@cro.it.
² Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
³ International PhD School in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.
⁴ Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
⁵ Hematology Unit, Department of Oncology and Hematology, Azienda-Ospedaliero Universitaria (AOU) of Modena, Policlinico, Modena, Italy.
⁶ Department of Medical and Surgical Sciences, University of Modena e Reggio Emilia, Modena, Italy.
⁷ Division of Ematologia, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.
⁸ Fondazione Universitaria Policlinico A Gemelli di Roma, Roma, Italy.
⁹ Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi" DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy.
¹⁰ Division of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
¹¹ Division of Haematology, University of Tor Vergata, Rome, Italy.
¹² Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
¹³ Hematology Unit AO of Cosenza, Cosenza, Italy.
¹⁴ Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
¹⁵ Hematology Oncology Department, Augusta Victoria Hospital, East Jerusalem, Israel.
¹⁶ Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
¹⁷ Department of Clinical and Molecular Medicine and Hematology, Sant'Andrea - University Hospital - Sapienza, University of Rome, Rome, Italy.
¹⁸ Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
¹⁹ Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
²⁰ Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy. vgattei@cro.it.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / therapeutic use
Drug Resistance, Neoplasm
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Piperidines / therapeutic use
Tumor Suppressor Protein p53 / genetics

Substances

Adenine
ibrutinib
Piperidines
TP53 protein, human
Tumor Suppressor Protein p53